The global landscape of smallpox vaccination history and implications for current and future orthopoxvirus susceptibility: a modelling study - 23/03/23
Summary |
Background |
More than four decades after the eradication of smallpox, the ongoing 2022 monkeypox outbreak and increasing transmission events of other orthopoxviruses necessitate a greater understanding of the global distribution of susceptibility to orthopoxviruses. We aimed to characterise the current global landscape of smallpox vaccination history and orthopoxvirus susceptibility.
Methods |
We characterised the global landscape of smallpox vaccination at a subnational scale by integrating data on current demography with historical smallpox vaccination programme features (coverage and cessation dates) from eradication documents and published literature. We analysed this landscape to identify the factors that were most associated with geographical heterogeneity in current vaccination coverage. We considered how smallpox vaccination history might translate into age-specific susceptibility profiles for orthopoxviruses under different vaccination effectiveness scenarios.
Findings |
We found substantial global spatial heterogeneity in the landscape of smallpox vaccination, with vaccination coverage estimated to range from 7% to 60% within admin-1 regions (ie, regions one administrative level below country) globally, with negligible uncertainty (99·6% of regions have an SD less than 5%). We identified that geographical variation in vaccination coverage was driven mostly by differences in subnational demography. Additionally, we found that susceptibility for orthopoxviruses was highly age specific based on age at cessation and age-specific coverage; however, the age profile was consistent across vaccine effectiveness values.
Interpretation |
The legacy of smallpox eradication can be observed in the current landscape of smallpox vaccine protection. The strength and longevity of smallpox vaccination campaigns globally, combined with current demographic heterogeneity, have shaped the epidemiological landscape today, revealing substantial geographical variation in orthopoxvirus susceptibility. This study alerts public health decision makers to non-endemic regions that might be at greatest risk in the case of widespread and sustained transmission in the 2022 monkeypox outbreak and highlights the importance of demography and fine-scale spatial dynamics in predicting future public health risks from orthopoxviruses.
Funding |
US National Institutes of Health and US National Science Foundation.
Le texte complet de cet article est disponible en PDF.Plan
Vol 23 - N° 4
P. 454-462 - avril 2023 Retour au numéro
Article précédent
- Viral dynamics in patients with monkeypox infection: a prospective cohort study in Spain
- Clara Suñer, Maria Ubals, Eloy José Tarín-Vicente, Adrià Mendoza, Andrea Alemany, Águeda Hernández-Rodríguez, Cristina Casañ, Vicente Descalzo, Dan Ouchi, Aurélien Marc, Àngel Rivero, Pep Coll, Xènia Oller, José Miguel Cabrera, Martí Vall-Mayans, María Dolores Folgueira, María Ángeles Melendez, Manuel Agud-Dios, Elena Gil-Cruz, Alexia Paris de Leon, Aída Ramírez Marinero, Vira Buhiichyk, Cristina Galván-Casas, Roger Paredes, Nuria Prat, Maria-Rosa Sala Farre, Josep Maria Bonet-Simó, Magí Farré, Pablo L Ortiz-Romero, Bonaventura Clotet, Vicente García-Patos, Jordi Casabona, Jeremie Guedj, Pere-Joan Cardona, Ignacio Blanco, The Movie Group, Michael Marks, Oriol Mitjà, José Ramón Santos, Lucía Bailón, Susana Benet, Jorge Arroyo Andres, Lorena Calderón Lozano, María Carrasco Díaz, Carla Budria Serrano, Enola Crespillo Galán, Ana Isabel Parra Manzano, Pamela Nef Rabadán, Laura Muntané, Cristina Sánchez-Lafuente Doncel, Yesinei Marina Marrero Pueo, Aroa Muñoz Quinto, Marlon Acosta, Patricia Alvarez, Maider Arando, Jorge N García, Arnau Monforte, Yolanda Maltas Hidalgo, Ramona Hervas Perez, Laura Clotet Romero
- Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial
- Victor Kande Betu Kumeso, Wilfried Mutombo Kalonji, Sandra Rembry, Olaf Valverde Mordt, Digas Ngolo Tete, Adeline Prêtre, Sophie Delhomme, Médard Ilunga Wa Kyhi, Mamadou Camara, Julie Catusse, Stefan Schneitter, Morgane Nusbaumer, Erick Mwamba Miaka, Hélène Mahenzi Mbembo, Joseph Makaya Mayawula, Mariame Layba Camara, Félix Akwaso Massa, Lewis Kaninda Badibabi, Augustin Kasongo Bonama, Papy Kavunga Lukula, Sylvain Mutanda Kalonji, Phyll Mariero Philemon, Ricardo Mokilifi Nganyonyi, Hugues Embana Mankiara, André Asuka Akongo Nguba, Vincent Kobo Muanza, Ernest Mulenge Nasandhel, Aimée Fifi Nzeza Bambuwu, Bruno Scherrer, Nathalie Strub-Wourgaft, Antoine Tarral
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?